CJC-1295 research guide for Al-`Ula. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Al-`Ula looking to source CJC-1295, the foundational reality is that this compound is available only through an online research supply market. What this means for Al-`Ula researchers is that physical proximity is irrelevant compared to your ability to verify analytical documentation — and those quality checks are within reach of all serious researchers. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. Use this guide to verify vendor quality systematically — the framework here work regardless of your location.
The Science Behind CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Al-`Ula comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Assessing CJC-1295 vendors begins with the COA: access the batch-specific certificate before purchasing, not after. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be 98% or higher. The combination of peer feedback and direct document verification is the most effective quality filter — community feedback surfaces systemic problems invisible in one transaction, and vice versa. Store lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order CJC-1295 — ships to Al-`Ula
COA-verified · International tracking · Research grade
All use of CJC-1295 in Al-`Ula or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Proper handling of CJC-1295 requires careful sterile procedure — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and consistent cold chain handling. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no discount compensates for this missing data. Researchers combining CJC-1295 with other compounds should check the research literature for any reported interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
